- About MEDx
- Technology Centers
- Pharma Solutions
-
CDx/IVD Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized Assays - Clinical Testing
- Quality Systems
- Events
- Contact Us
The Pan-Solid Tumor 95- Gene Panel Assay is a small panel product for solid tumors independently developed by MEDx Translational Medicine. It covers relevant genes with clear drug significance recommended by authoritative guidelines. Probe-Based Hybridization Capture and Next Generation Sequencing (NGS) are used in the procedure. NGS technology can detect point mutations, insertion/deletion, copy number variation, fusion/rearrangement, and various mutation types. Pan-solid tumor 95-gene panel assay are highly expandable and has been packaged into even small panels of genes used for detecting single cancer, such as lung cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, and gastrointestinal stromal tumor, in order to offer cost-effective panel gene assays in clinic. The detection scheme meets the needs of patients treated with the right options of targeted drugs, chemical drugs, and immunotherapy.
NGS
Full detection range, fast reporting cycle and highly efficient performance
Pan-solid tumors
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D
